{
  "symbol": "ABBV",
  "year": 2025,
  "Period": "Q2",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.2669,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.073
  },
  "top_positive": [
    {
      "sent": "The following table details AbbVie\u2019s worldwide net revenues: Three months ended March 31, (in\u00a0millions) 2025 2024 Immunology Skyrizi United States $ 2,919 $ 1,656 International 506 352 Total $ 3,425 $ 2,008 Rinvoq United States $ 1,220 $ 725 International 498 368 Total $ 1,718 $ 1,093 Humira United States $ 744 $ 1,771 International 377 499 Total $ 1,121 $ 2,270 Neuroscience Vraylar United States $ 763 $ 692 International 2 2 Total $ 765 $ 694 Botox Therapeutic United States $ 723 $ 611 International 143 137 Total $ 866 $ 748 Ubrelvy United States $ 233 $ 197 International 7 6 Total $ 240 $ 203 Qulipta United States $ 172 $ 128 International 21 3 Total $ 193 $ 131 Vyalev United States $ 6 $ \u2014 International 57 9 Total $ 63 $ 9 Duodopa United States $ 20 $ 25 International 76 90 Total $ 96 $ 115 Other Neuroscience United States $ 55 $ 61 International 4 4 Total $ 59 $ 65 2025 Form 10-Q | 23 Three months ended March 31, (in\u00a0millions) 2025 2024 Oncology Imbruvica United States $ 529 $ 610 Collaboration revenues 209 228 Total $ 738 $ 838 Venclexta United States $ 312 $ 281 International 353 333 Total $ 665 $ 614 Elahere United States $ 165 $ 64 International 14 \u2014 Total $ 179 $ 64 Epkinly Collaboration revenues $ 36 $ 22 International 15 5 Total $ 51 $ 27 Aesthetics Botox Cosmetic United States $ 295 $ 389 International 261 244 Total $ 556 $ 633 Juvederm Collection United States $ 75 $ 106 International 156 191 Total $ 231 $ 297 Other Aesthetics United States $ 270 $ 281 International 45 38 Total $ 315 $ 319 Eye Care Ozurdex United States $ 30 $ 34 International 93 97 Total $ 123 $ 131 Lumigan/Ganfort United States $ 48 $ 29 International 58 62 Total $ 106 $ 91 Alphagan/Combigan United States $ 26 $ 15 International 34 44 Total $ 60 $ 59 Other Eye Care United States $ 117 $ 149 International 100 108 Total $ 217 $ 257 Other Key Products Mavyret United States $ 142 $ 144 International 164 205 Total $ 306 $ 349 Creon United States $ 355 $ 285 Linzess/Constella United States $ 139 $ 257 International 9 9 Total $ 148 $ 266 All other $ 747 $ 744 Total net revenues $ 13,343 $ 12,310 See the following for additional information about certain income and expenses included in net earnings: intangible assets amortization expense (Note 6), change in fair value of contingent consideration (Note 8), interest income and expense (Note 2), depreciation expense (Note 2), litigation matters (Note 12), income tax expense (Note 11) and restructuring expense (Note 7).",
      "score": 0.9976
    },
    {
      "sent": "Three months ended March 31, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2025 2024 United States $ 9,979 $ 9,041 10.4 % 10.4 % International 3,364 3,269 2.9 % 8.3 % Net revenues $ 13,343 $ 12,310 8.4 % 9.8 % 2025 Form 10-Q | 27 The following table details AbbVie\u2019s worldwide net revenues: Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2025 2024 Immunology Skyrizi United States $ 2,919 $ 1,656 76.2 % 76.2 % International 506 352 43.9 % 52.3 % Total $ 3,425 $ 2,008 70.5 % 72.0 % Rinvoq United States $ 1,220 $ 725 68.3 % 68.3 % International 498 368 35.3 % 42.8 % Total $ 1,718 $ 1,093 57.2 % 59.7 % Humira United States $ 744 $ 1,771 (58.0) % (58.0) % International 377 499 (24.4) % (19.5) % Total $ 1,121 $ 2,270 (50.6) % (49.5) % Neuroscience Vraylar United States $ 763 $ 692 10.3 % 10.3 % International 2 2 13.1 % 20.2 % Total $ 765 $ 694 10.3 % 10.3 % Botox Therapeutic United States $ 723 $ 611 18.2 % 18.2 % International 143 137 4.8 % 11.4 % Total $ 866 $ 748 15.8 % 17.0 % Ubrelvy United States $ 233 $ 197 17.6 % 17.6 % International 7 6 23.3 % 29.3 % Total $ 240 $ 203 17.8 % 18.0 % Qulipta United States $ 172 $ 128 34.2 % 34.2 % International 21 3 >100.0 % >100.0 % Total $ 193 $ 131 47.6 % 48.3 % Vyalev United States $ 6 $ \u2014 n/m n/m International 57 9 >100.0 % >100.0 % Total $ 63 $ 9 >100.0 % >100.0 % Duodopa United States $ 20 $ 25 (19.4) % (19.4) % International 76 90 (16.0) % (11.7) % Total $ 96 $ 115 (16.7) % (13.3) % Other Neuroscience United States $ 55 $ 61 (9.5) % (9.5) % International 4 4 (1.0) % 6.5 % Total $ 59 $ 65 (8.9) % (8.4) % Oncology Imbruvica United States $ 529 $ 610 (13.3) % (13.3) % Collaboration revenues 209 228 (8.2) % (8.2) % Total $ 738 $ 838 (11.9) % (11.9) % Venclexta United States $ 312 $ 281 11.0 % 11.0 % International 353 333 6.0 % 13.4 % Total $ 665 $ 614 8.3 % 12.3 % Elahere United States $ 165 $ 64 >100.0 % >100.0 % International 14 \u2014 n/m n/m Total $ 179 $ 64 >100.0 % >100.0 % Epkinly Collaboration revenues $ 36 $ 22 62.1 % 62.1 % International 15 5 >100.0 % >100.0 % Total $ 51 $ 27 89.8 % 94.8 % Aesthetics Botox Cosmetic United States $ 295 $ 389 (24.3) % (24.3) % International 261 244 6.9 % 11.1 % Total $ 556 $ 633 (12.3) % (10.7) % 2025 Form 10-Q | 28 Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2025 2024 Juvederm Collection United States $ 75 $ 106 (29.0) % (29.0) % International 156 191 (18.5) % (15.0) % Total $ 231 $ 297 (22.2) % (20.0) % Other Aesthetics United States $ 270 $ 281 (3.5) % (3.5) % International 45 38 18.1 % 23.2 % Total $ 315 $ 319 (0.9) % (0.3) % Eye Care Ozurdex United States $ 30 $ 34 (12.1) % (12.1) % International 93 97 (3.8) % 1.1 % Total $ 123 $ 131 (6.0) % (2.4) % Lumigan/Ganfort United States $ 48 $ 29 69.2 % 69.2 % International 58 62 (6.8) % (0.5) % Total $ 106 $ 91 17.0 % 21.4 % Alphagan/Combigan United States $ 26 $ 15 68.5 % 68.5 % International 34 44 (21.4) % (15.4) % Total $ 60 $ 59 1.9 % 6.3 % Other Eye Care United States $ 117 $ 149 (21.4) % (21.4) % International 100 108 (7.1) % (0.2) % Total $ 217 $ 257 (15.4) % (12.5) % Other Key Products Mavyret United States $ 142 $ 144 (0.7) % (0.7) % International 164 205 (20.4) % (15.8) % Total $ 306 $ 349 (12.3) % (9.6) % Creon United States $ 355 $ 285 24.6 % 24.6 % Linzess/Constella United States $ 139 $ 257 (46.1) % (46.1) % International 9 9 3.1 % 9.3 % Total $ 148 $ 266 (44.4) % (44.2) % All other $ 747 $ 744 0.1 % 0.7 % Total net revenues $ 13,343 $ 12,310 8.4 % 9.8 % n/m \u2013 Not meaningful The following discussion and analysis of AbbVie\u2019s net revenues by product is presented on a constant currency basis.",
      "score": 0.997
    },
    {
      "sent": "Three months ended March 31, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2025 2024 United States $ 9,979 $ 9,041 10.4 % 10.4 % International 3,364 3,269 2.9 % 8.3 % Net revenues $ 13,343 $ 12,310 8.4 % 9.8 % 2025 Form 10-Q | 27 The following table details AbbVie\u2019s worldwide net revenues: Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2025 2024 Immunology Skyrizi United States $ 2,919 $ 1,656 76.2 % 76.2 % International 506 352 43.9 % 52.3 % Total $ 3,425 $ 2,008 70.5 % 72.0 % Rinvoq United States $ 1,220 $ 725 68.3 % 68.3 % International 498 368 35.3 % 42.8 % Total $ 1,718 $ 1,093 57.2 % 59.7 % Humira United States $ 744 $ 1,771 (58.0) % (58.0) % International 377 499 (24.4) % (19.5) % Total $ 1,121 $ 2,270 (50.6) % (49.5) % Neuroscience Vraylar United States $ 763 $ 692 10.3 % 10.3 % International 2 2 13.1 % 20.2 % Total $ 765 $ 694 10.3 % 10.3 % Botox Therapeutic United States $ 723 $ 611 18.2 % 18.2 % International 143 137 4.8 % 11.4 % Total $ 866 $ 748 15.8 % 17.0 % Ubrelvy United States $ 233 $ 197 17.6 % 17.6 % International 7 6 23.3 % 29.3 % Total $ 240 $ 203 17.8 % 18.0 % Qulipta United States $ 172 $ 128 34.2 % 34.2 % International 21 3 >100.0 % >100.0 % Total $ 193 $ 131 47.6 % 48.3 % Vyalev United States $ 6 $ \u2014 n/m n/m International 57 9 >100.0 % >100.0 % Total $ 63 $ 9 >100.0 % >100.0 % Duodopa United States $ 20 $ 25 (19.4) % (19.4) % International 76 90 (16.0) % (11.7) % Total $ 96 $ 115 (16.7) % (13.3) % Other Neuroscience United States $ 55 $ 61 (9.5) % (9.5) % International 4 4 (1.0) % 6.5 % Total $ 59 $ 65 (8.9) % (8.4) % Oncology Imbruvica United States $ 529 $ 610 (13.3) % (13.3) % Collaboration revenues 209 228 (8.2) % (8.2) % Total $ 738 $ 838 (11.9) % (11.9) % Venclexta United States $ 312 $ 281 11.0 % 11.0 % International 353 333 6.0 % 13.4 % Total $ 665 $ 614 8.3 % 12.3 % Elahere United States $ 165 $ 64 >100.0 % >100.0 % International 14 \u2014 n/m n/m Total $ 179 $ 64 >100.0 % >100.0 % Epkinly Collaboration revenues $ 36 $ 22 62.1 % 62.1 % International 15 5 >100.0 % >100.0 % Total $ 51 $ 27 89.8 % 94.8 % Aesthetics Botox Cosmetic United States $ 295 $ 389 (24.3) % (24.3) % International 261 244 6.9 % 11.1 % Total $ 556 $ 633 (12.3) % (10.7) % 2025 Form 10-Q | 28 Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2025 2024 Juvederm Collection United States $ 75 $ 106 (29.0) % (29.0) % International 156 191 (18.5) % (15.0) % Total $ 231 $ 297 (22.2) % (20.0) % Other Aesthetics United States $ 270 $ 281 (3.5) % (3.5) % International 45 38 18.1 % 23.2 % Total $ 315 $ 319 (0.9) % (0.3) % Eye Care Ozurdex United States $ 30 $ 34 (12.1) % (12.1) % International 93 97 (3.8) % 1.1 % Total $ 123 $ 131 (6.0) % (2.4) % Lumigan/Ganfort United States $ 48 $ 29 69.2 % 69.2 % International 58 62 (6.8) % (0.5) % Total $ 106 $ 91 17.0 % 21.4 % Alphagan/Combigan United States $ 26 $ 15 68.5 % 68.5 % International 34 44 (21.4) % (15.4) % Total $ 60 $ 59 1.9 % 6.3 % Other Eye Care United States $ 117 $ 149 (21.4) % (21.4) % International 100 108 (7.1) % (0.2) % Total $ 217 $ 257 (15.4) % (12.5) % Other Key Products Mavyret United States $ 142 $ 144 (0.7) % (0.7) % International 164 205 (20.4) % (15.8) % Total $ 306 $ 349 (12.3) % (9.6) % Creon United States $ 355 $ 285 24.6 % 24.6 % Linzess/Constella United States $ 139 $ 257 (46.1) % (46.1) % International 9 9 3.1 % 9.3 % Total $ 148 $ 266 (44.4) % (44.2) % All other $ 747 $ 744 0.1 % 0.7 % Total net revenues $ 13,343 $ 12,310 8.4 % 9.8 % n/m \u2013 Not meaningful The following discussion and analysis of AbbVie\u2019s net revenues by product is presented on a constant currency basis.",
      "score": 0.997
    }
  ],
  "top_negative": [
    {
      "sent": "Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.",
      "score": -0.8779
    },
    {
      "sent": "These inherent limitations include the realities that 2025 Form 10-Q | 33 judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake.",
      "score": -0.7506
    },
    {
      "sent": "AbbVie\u2019s management, including its Chief Executive Officer and its Chief Financial Officer, do not expect that AbbVie\u2019s disclosure controls or internal control over financial reporting will prevent or detect all errors and all fraud.",
      "score": -0.7269
    }
  ],
  "forward_snippets": [
    "AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements.",
    "AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements.",
    "Cerevel Therapeutics neuroscience pipeline included multiple clinical-stage and preclinical candidates with the potential to treat several diseases including schizophrenia, Parkinson's disease and mood disorders.",
    "ImmunoGen's oncology portfolio included its flagship cancer therapy Elahere, a first-in-class ADC approved for platinum-resistant ovarian cancer, and a pipeline of promising next-generation ADC's targeting hematologic malignancies and solid tumors.",
    "AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements."
  ],
  "curated_text": "Symbol: ABBV. Year: 2025. Period: Q2. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: The following table details AbbVie\u2019s worldwide net revenues: Three months ended March 31, (in\u00a0millions) 2025 2024 Immunology Skyrizi United States $ 2,919 $ 1,656 International 506 352 Total $ 3,425 $ 2,008 Rinvoq United States $ 1,220 $ 725 International 498 368 Total $ 1,718 $ 1,093 Humira United States $ 744 $ 1,771 International 377 499 Total $ 1,121 $ 2,270 Neuroscience Vraylar United States $ 763 $ 692 International 2 2 Total $ 765 $ 694 Botox Therapeutic United States $ 723 $ 611 International 143 137 Total $ 866 $ 748 Ubrelvy United States $ 233 $ 197 International 7 6 Total $ 240 $ 203 Qulipta United States $ 172 $ 128 International 21 3 Total $ 193 $ 131 Vyalev United States $ 6 $ \u2014 International 57 9 Total $ 63 $ 9 Duodopa United States $ 20 $ 25 International 76 90 Total $ 96 $ 115 Other Neuroscience United States $ 55 $ 61 International 4 4 Total $ 59 $ 65 2025 Form 10-Q | 23 Three months ended March 31, (in\u00a0millions) 2025 2024 Oncology Imbruvica United States $ 529 $ 610 Collaboration revenues 209 228 Total $ 738 $ 838 Venclexta United States $ 312 $ 281 International 353 333 Total $ 665 $ 614 Elahere United States $ 165 $ 64 International 14 \u2014 Total $ 179 $ 64 Epkinly Collaboration revenues $ 36 $ 22 International 15 5 Total $ 51 $ 27 Aesthetics Botox Cosmetic United States $ 295 $ 389 International 261 244 Total $ 556 $ 633 Juvederm Collection United States $ 75 $ 106 International 156 191 Total $ 231 $ 297 Other Aesthetics United States $ 270 $ 281 International 45 38 Total $ 315 $ 319 Eye Care Ozurdex United States $ 30 $ 34 International 93 97 Total $ 123 $ 131 Lumigan/Ganfort United States $ 48 $ 29 International 58 62 Total $ 106 $ 91 Alphagan/Combigan United States $ 26 $ 15 International 34 44 Total $ 60 $ 59 Other Eye Care United States $ 117 $ 149 International 100 108 Total $ 217 $ 257 Other Key Products Mavyret United States $ 142 $ 144 International 164 205 Total $ 306 $ 349 Creon United States $ 355 $ 285 Linzess/Constella United States $ 139 $ 257 International 9 9 Total $ 148 $ 266 All other $ 747 $ 744 Total net revenues $ 13,343 $ 12,310 See the following for additional information about certain income and expenses included in net earnings: intangible assets amortization expense (Note 6), change in fair value of contingent consideration (Note 8), interest income and expense (Note 2), depreciation expense (Note 2), litigation matters (Note 12), income tax expense (Note 11) and restructuring expense (Note 7). Three months ended March 31, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2025 2024 United States $ 9,979 $ 9,041 10.4 % 10.4 % International 3,364 3,269 2.9 % 8.3 % Net revenues $ 13,343 $ 12,310 8.4 % 9.8 % 2025 Form 10-Q | 27 The following table details AbbVie\u2019s worldwide net revenues: Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2025 2024 Immunology Skyrizi United States $ 2,919 $ 1,656 76.2 % 76.2 % International 506 352 43.9 % 52.3 % Total $ 3,425 $ 2,008 70.5 % 72.0 % Rinvoq United States $ 1,220 $ 725 68.3 % 68.3 % International 498 368 35.3 % 42.8 % Total $ 1,718 $ 1,093 57.2 % 59.7 % Humira United States $ 744 $ 1,771 (58.0) % (58.0) % International 377 499 (24.4) % (19.5) % Total $ 1,121 $ 2,270 (50.6) % (49.5) % Neuroscience Vraylar United States $ 763 $ 692 10.3 % 10.3 % International 2 2 13.1 % 20.2 % Total $ 765 $ 694 10.3 % 10.3 % Botox Therapeutic United States $ 723 $ 611 18.2 % 18.2 % International 143 137 4.8 % 11.4 % Total $ 866 $ 748 15.8 % 17.0 % Ubrelvy United States $ 233 $ 197 17.6 % 17.6 % International 7 6 23.3 % 29.3 % Total $ 240 $ 203 17.8 % 18.0 % Qulipta United States $ 172 $ 128 34.2 % 34.2 % International 21 3 >100.0 % >100.0 % Total $ 193 $ 131 47.6 % 48.3 % Vyalev United States $ 6 $ \u2014 n/m n/m International 57 9 >100.0 % >100.0 % Total $ 63 $ 9 >100.0 % >100.0 % Duodopa United States $ 20 $ 25 (19.4) % (19.4) % International 76 90 (16.0) % (11.7) % Total $ 96 $ 115 (16.7) % (13.3) % Other Neuroscience United States $ 55 $ 61 (9.5) % (9.5) % International 4 4 (1.0) % 6.5 % Total $ 59 $ 65 (8.9) % (8.4) % Oncology Imbruvica United States $ 529 $ 610 (13.3) % (13.3) % Collaboration revenues 209 228 (8.2) % (8.2) % Total $ 738 $ 838 (11.9) % (11.9) % Venclexta United States $ 312 $ 281 11.0 % 11.0 % International 353 333 6.0 % 13.4 % Total $ 665 $ 614 8.3 % 12.3 % Elahere United States $ 165 $ 64 >100.0 % >100.0 % International 14 \u2014 n/m n/m Total $ 179 $ 64 >100.0 % >100.0 % Epkinly Collaboration revenues $ 36 $ 22 62.1 % 62.1 % International 15 5 >100.0 % >100.0 % Total $ 51 $ 27 89.8 % 94.8 % Aesthetics Botox Cosmetic United States $ 295 $ 389 (24.3) % (24.3) % International 261 244 6.9 % 11.1 % Total $ 556 $ 633 (12.3) % (10.7) % 2025 Form 10-Q | 28 Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2025 2024 Juvederm Collection United States $ 75 $ 106 (29.0) % (29.0) % International 156 191 (18.5) % (15.0) % Total $ 231 $ 297 (22.2) % (20.0) % Other Aesthetics United States $ 270 $ 281 (3.5) % (3.5) % International 45 38 18.1 % 23.2 % Total $ 315 $ 319 (0.9) % (0.3) % Eye Care Ozurdex United States $ 30 $ 34 (12.1) % (12.1) % International 93 97 (3.8) % 1.1 % Total $ 123 $ 131 (6.0) % (2.4) % Lumigan/Ganfort United States $ 48 $ 29 69.2 % 69.2 % International 58 62 (6.8) % (0.5) % Total $ 106 $ 91 17.0 % 21.4 % Alphagan/Combigan United States $ 26 $ 15 68.5 % 68.5 % International 34 44 (21.4) % (15.4) % Total $ 60 $ 59 1.9 % 6.3 % Other Eye Care United States $ 117 $ 149 (21.4) % (21.4) % International 100 108 (7.1) % (0.2) % Total $ 217 $ 257 (15.4) % (12.5) % Other Key Products Mavyret United States $ 142 $ 144 (0.7) % (0.7) % International 164 205 (20.4) % (15.8) % Total $ 306 $ 349 (12.3) % (9.6) % Creon United States $ 355 $ 285 24.6 % 24.6 % Linzess/Constella United States $ 139 $ 257 (46.1) % (46.1) % International 9 9 3.1 % 9.3 % Total $ 148 $ 266 (44.4) % (44.2) % All other $ 747 $ 744 0.1 % 0.7 % Total net revenues $ 13,343 $ 12,310 8.4 % 9.8 % n/m \u2013 Not meaningful The following discussion and analysis of AbbVie\u2019s net revenues by product is presented on a constant currency basis. Three months ended March 31, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2025 2024 United States $ 9,979 $ 9,041 10.4 % 10.4 % International 3,364 3,269 2.9 % 8.3 % Net revenues $ 13,343 $ 12,310 8.4 % 9.8 % 2025 Form 10-Q | 27 The following table details AbbVie\u2019s worldwide net revenues: Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2025 2024 Immunology Skyrizi United States $ 2,919 $ 1,656 76.2 % 76.2 % International 506 352 43.9 % 52.3 % Total $ 3,425 $ 2,008 70.5 % 72.0 % Rinvoq United States $ 1,220 $ 725 68.3 % 68.3 % International 498 368 35.3 % 42.8 % Total $ 1,718 $ 1,093 57.2 % 59.7 % Humira United States $ 744 $ 1,771 (58.0) % (58.0) % International 377 499 (24.4) % (19.5) % Total $ 1,121 $ 2,270 (50.6) % (49.5) % Neuroscience Vraylar United States $ 763 $ 692 10.3 % 10.3 % International 2 2 13.1 % 20.2 % Total $ 765 $ 694 10.3 % 10.3 % Botox Therapeutic United States $ 723 $ 611 18.2 % 18.2 % International 143 137 4.8 % 11.4 % Total $ 866 $ 748 15.8 % 17.0 % Ubrelvy United States $ 233 $ 197 17.6 % 17.6 % International 7 6 23.3 % 29.3 % Total $ 240 $ 203 17.8 % 18.0 % Qulipta United States $ 172 $ 128 34.2 % 34.2 % International 21 3 >100.0 % >100.0 % Total $ 193 $ 131 47.6 % 48.3 % Vyalev United States $ 6 $ \u2014 n/m n/m International 57 9 >100.0 % >100.0 % Total $ 63 $ 9 >100.0 % >100.0 % Duodopa United States $ 20 $ 25 (19.4) % (19.4) % International 76 90 (16.0) % (11.7) % Total $ 96 $ 115 (16.7) % (13.3) % Other Neuroscience United States $ 55 $ 61 (9.5) % (9.5) % International 4 4 (1.0) % 6.5 % Total $ 59 $ 65 (8.9) % (8.4) % Oncology Imbruvica United States $ 529 $ 610 (13.3) % (13.3) % Collaboration revenues 209 228 (8.2) % (8.2) % Total $ 738 $ 838 (11.9) % (11.9) % Venclexta United States $ 312 $ 281 11.0 % 11.0 % International 353 333 6.0 % 13.4 % Total $ 665 $ 614 8.3 % 12.3 % Elahere United States $ 165 $ 64 >100.0 % >100.0 % International 14 \u2014 n/m n/m Total $ 179 $ 64 >100.0 % >100.0 % Epkinly Collaboration revenues $ 36 $ 22 62.1 % 62.1 % International 15 5 >100.0 % >100.0 % Total $ 51 $ 27 89.8 % 94.8 % Aesthetics Botox Cosmetic United States $ 295 $ 389 (24.3) % (24.3) % International 261 244 6.9 % 11.1 % Total $ 556 $ 633 (12.3) % (10.7) % 2025 Form 10-Q | 28 Three months ended March 31, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2025 2024 Juvederm Collection United States $ 75 $ 106 (29.0) % (29.0) % International 156 191 (18.5) % (15.0) % Total $ 231 $ 297 (22.2) % (20.0) % Other Aesthetics United States $ 270 $ 281 (3.5) % (3.5) % International 45 38 18.1 % 23.2 % Total $ 315 $ 319 (0.9) % (0.3) % Eye Care Ozurdex United States $ 30 $ 34 (12.1) % (12.1) % International 93 97 (3.8) % 1.1 % Total $ 123 $ 131 (6.0) % (2.4) % Lumigan/Ganfort United States $ 48 $ 29 69.2 % 69.2 % International 58 62 (6.8) % (0.5) % Total $ 106 $ 91 17.0 % 21.4 % Alphagan/Combigan United States $ 26 $ 15 68.5 % 68.5 % International 34 44 (21.4) % (15.4) % Total $ 60 $ 59 1.9 % 6.3 % Other Eye Care United States $ 117 $ 149 (21.4) % (21.4) % International 100 108 (7.1) % (0.2) % Total $ 217 $ 257 (15.4) % (12.5) % Other Key Products Mavyret United States $ 142 $ 144 (0.7) % (0.7) % International 164 205 (20.4) % (15.8) % Total $ 306 $ 349 (12.3) % (9.6) % Creon United States $ 355 $ 285 24.6 % 24.6 % Linzess/Constella United States $ 139 $ 257 (46.1) % (46.1) % International 9 9 3.1 % 9.3 % Total $ 148 $ 266 (44.4) % (44.2) % All other $ 747 $ 744 0.1 % 0.7 % Total net revenues $ 13,343 $ 12,310 8.4 % 9.8 % n/m \u2013 Not meaningful The following discussion and analysis of AbbVie\u2019s net revenues by product is presented on a constant currency basis. Top negative sentences: Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that 2025 Form 10-Q | 33 judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. AbbVie\u2019s management, including its Chief Executive Officer and its Chief Financial Officer, do not expect that AbbVie\u2019s disclosure controls or internal control over financial reporting will prevent or detect all errors and all fraud. Forward-looking snippets: AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements. AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements. Cerevel Therapeutics neuroscience pipeline included multiple clinical-stage and preclinical candidates with the potential to treat several diseases including schizophrenia, Parkinson's disease and mood disorders. ImmunoGen's oncology portfolio included its flagship cancer therapy Elahere, a first-in-class ADC approved for platinum-resistant ovarian cancer, and a pipeline of promising next-generation ADC's targeting hematologic malignancies and solid tumors. AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements."
}